10 completed, 7 terminated, 1 withdrawn. 10 Phase 3, 5 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 10 | Completed 5, Terminated 4, Withdrawn 1 |
| Phase 2 | 5 | Terminated 3, Completed 2 |
| Phase 1 | 3 | Completed 3 |
Follow GLYX-13 peptide: new trials by email Literature Review of GLYX-13 peptide trials Research Report on GLYX-13 peptide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Rapastinel as Monotherapy in Major Depressive Disorder (MDD) Rapastinel, Vortioxetine, Placebo - Depressive Disorder, Major | Phase 3 | Withdrawn | Naurex, Inc, an affiliate of Allergan plc | 2019-07-01 | 2019-07-19 | |
| Assessment of Effect of Rapastinel on Driving Performance Rapastinel, Alprazolam, Ketamine - Driving Performance | Phase 1 | Completed | Naurex, Inc, an affiliate of Allergan plc | 107 | 2018-11-05 | 2019-07-11 |
| Assessment of Abuse Potential of Rapastinel in Humans Rapastinel, Ketamine, Placebo - Human Abuse Potential | Phase 1 | Completed | Naurex, Inc, an affiliate of Allergan plc | 72 | 2018-11-01 | 2019-05-16 |
| Study of Rapastinel as Monotherapy in Patients With Major Depressive Disorder (MDD) Rapastinel, Placebo - Depressive Disorder, Major | Phase 3 | Terminated | Naurex, Inc, an affiliate of Allergan plc | 50 | 2018-10-30 | 2020-07-28 |
| Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD) Rapastinel - Depressive Disorder, Major | Phase 3 | Terminated | Naurex, Inc, an affiliate of Allergan plc | 230 | 2018-08-23 | 2020-07-17 |
| Study of Monotherapy Rapastinel in the Prevention of Relapse in Patients With Major Depressive Disorder (MDD) Rapastinel, Placebo - Depressive Disorder, Major | Phase 3 | Terminated | Naurex, Inc, an affiliate of Allergan plc | 363 | 2018-08-02 | 2020-10-09 |
| Study of Rapastinel as Monotherapy in Patients With MDD Rapastinel, Placebo - Depressive Disorder, Major | Phase 3 | Terminated | Naurex, Inc, an affiliate of Allergan plc | 439 | 2018-06-15 | 2020-09-01 |
| A Study of Rapastinel for Rapid Treatment of Depression and Suicidality in Major Depressive Disorder Rapastinel, Placebo - Depressive Disorder, Major | Phase 2 | Terminated | Naurex, Inc, an affiliate of Allergan plc | 138 | 2017-12-15 | 2020-08-14 |
| Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder Rapastinel - Depressive Disorder, Major | Phase 3 | Completed | Naurex, Inc, an affiliate of Allergan plc | 617 | 2017-02-03 | 2020-06-22 |
| A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder Rapastinel, Placebo-matching Rapastinel - Depressive Disorder, Major | Phase 3 | Completed | Naurex, Inc, an affiliate of Allergan plc | 1304 | 2016-11-13 | 2020-03-09 |
| A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-03) Rapastinel, Placebo - Depressive Disorder, Major | Phase 3 | Completed | Naurex, Inc, an affiliate of Allergan plc | 429 | 2016-11-02 | 2019-11-13 |
| A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-02) Rapastinel, Placebo - Depressive Disorder, Major | Phase 3 | Completed | Naurex, Inc, an affiliate of Allergan plc | 658 | 2016-11-01 | 2019-12-27 |
| A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-01) Rapastinel, Placebo - Depressive Disorder, Major | Phase 3 | Completed | Naurex, Inc, an affiliate of Allergan plc | 465 | 2016-10-15 | 2019-10-11 |
| Open Label Trial of Rapastinel (Formerly GLYX-13) in Individuals With Obsessive-Compulsive Disorder Rapastinel (formerly GLYX-13) - Obsessive-Compulsive Disorder (OCD) | Phase 2 | Completed | New York State Psychiatric Institute | 7 | 2014-10-01 | 2017-07-18 |
| Open Label Extension for GLYX13-C-202, NCT01684163 Rapastinel (225 mg/450 mg IV administration) - Major Depressive Disorder | Phase 2 | Terminated | Naurex, Inc, an affiliate of Allergan plc | 61 | 2014-09-08 | 2019-11-27 |
| Effects of GLYX-13 on Learning and Memory in Healthy Individuals and Those With Psychiatric Illness GLYX-13, Placebo - Psychiatric Illness, Healthy | Phase 2 | Terminated | Northwestern University | 44 | 2013-05-01 | 2023-04-20 |
| Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression GLYX-13 - Major Depressive Disorder | Phase 2 | Completed | Naurex, Inc, an affiliate of Allergan plc | 115 | 2011-05-01 | 2012-09-12 |
| Single Ascending Dose Safety, Tolerability and Pharmacokinetics Study of GLYX-13 in Normal Volunteers GLYX-13, IV normal saline - Healthy | Phase 1 | Completed | Naurex, Inc, an affiliate of Allergan plc | 53 | 2009-11-01 | 2016-02-22 |
Depressive Disorder, Major (13) · Depression (5) · Mental Disorders (1) · Obsessive-Compulsive Disorder (1) · Psychotic Disorders (1) · Schizophrenia (1)
Naurex, Inc, an affiliate of Allergan plc (16) · New York State Psychiatric Institute (1) · Northwestern University (1)
United States (16) · Hungary (2) · Japan (2) · Poland (2) · Slovakia (2) · Canada (1) · Russia (1)
Jenna Hoogerheyde (11) · Sheng Fang Su (2) · Benji Kurian, MD (1) · Carolyn I Rodriguez, MD, PhD (1) · David Greuner, MD (1) · David Krefetz, DO (1) · James L Reilly, PhD (1) · Marc Debelle (1) · Matthew Macaluso, MD (1) · Michael Lesem, MD (1) · Neil Singla, MD (1) · Paul Gross, MD (1) · Raymond Manning, MD (1) · Ronald M Burch, MD, PhD (1) · Stephen Murray, MD PhD (1)
2018 (3)